Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
    2.
    发明申请
    Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk 有权
    Pro108抗体组合物和使用和使用Pro108来评估癌症风险的方法

    公开(公告)号:US20050124012A1

    公开(公告)日:2005-06-09

    申请号:US10919215

    申请日:2004-08-16

    摘要: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies. Other aspects of the invention are a method of killing an Pro108-expressing cancer cell, comprising contacting Pro108 present in the ECM with an anti-Pro108 antibody and a method of alleviating or treating an Pro108-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro108 antibody to the mammal.

    摘要翻译: 本发明涉及一种评估前列腺癌风险的方法。 具体来说,它涉及组合使用Pro108和前列腺特异性抗原(PSA)来确定前列腺癌的风险。 此外,它涉及使用Pro108或Pro108的特异性抗体评估卵巢癌,结肠癌,乳腺癌或胃癌的风险的方法。 本发明提供在体内在哺乳动物细胞上结合Pro108的分离的抗前列腺,卵巢,结肠,乳腺或胃癌抗原(Pro108)抗体。 本发明还包括包含抗Pro108抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro108抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Pro108抗体的细胞。 本发明包括产生抗Pro108抗体的方法。 本发明的其它方面是杀死表达Pro108的癌细胞的方法,包括使ECM中存在的Pro108与抗Pro108抗体接触,以及减轻或治疗哺乳动物中Pro108表达的癌症的方法,包括给予治疗 有效量的抗Pro108抗体。

    Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
    3.
    发明授权
    Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk 有权
    Pro108抗体组合物和使用和使用Pro108来评估癌症风险的方法

    公开(公告)号:US08148093B2

    公开(公告)日:2012-04-03

    申请号:US11866475

    申请日:2007-10-03

    摘要: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies. Other aspects of the invention are a method of killing an Pro108-expressing cancer cell, comprising contacting Pro108 present in the ECM with an anti-Pro108 antibody and a method of alleviating or treating an Pro108-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro108 antibody to the mammal.

    摘要翻译: 本发明涉及一种评估前列腺癌风险的方法。 具体来说,它涉及组合使用Pro108和前列腺特异性抗原(PSA)来确定前列腺癌的风险。 此外,它涉及使用Pro108或Pro108的特异性抗体评估卵巢癌,结肠癌,乳腺癌或胃癌的风险的方法。 本发明提供在体内在哺乳动物细胞上结合Pro108的分离的抗前列腺,卵巢,结肠,乳腺或胃癌抗原(Pro108)抗体。 本发明还包括包含抗Pro108抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro108抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Pro108抗体的细胞。 本发明包括产生抗Pro108抗体的方法。 本发明的其它方面是杀死表达Pro108的癌细胞的方法,包括使ECM中存在的Pro108与抗Pro108抗体接触,以及减轻或治疗哺乳动物中Pro108表达的癌症的方法,包括给予治疗 有效量的抗Pro108抗体。

    Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
    4.
    发明授权
    Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk 有权
    Pro108抗体组合物和使用和使用Pro108来评估癌症风险的方法

    公开(公告)号:US07294704B2

    公开(公告)日:2007-11-13

    申请号:US10919215

    申请日:2004-08-16

    IPC分类号: C07K16/00

    摘要: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies. Other aspects of the invention are a method of killing an Pro108-expressing cancer cell, comprising contacting Pro108 present in the ECM with an anti-Pro108 antibody and a method of alleviating or treating an Pro108-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro108 antibody to the mammal.

    摘要翻译: 本发明涉及一种评估前列腺癌风险的方法。 具体来说,它涉及组合使用Pro108和前列腺特异性抗原(PSA)来确定前列腺癌的风险。 此外,它涉及使用Pro108或Pro108的特异性抗体评估卵巢癌,结肠癌,乳腺癌或胃癌的风险的方法。 本发明提供在体内在哺乳动物细胞上结合Pro108的分离的抗前列腺,卵巢,结肠,乳腺或胃癌抗原(Pro108)抗体。 本发明还包括包含抗Pro108抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro108抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Pro108抗体的细胞。 本发明包括产生抗Pro108抗体的方法。 本发明的其它方面是杀死表达Pro108的癌细胞的方法,包括使ECM中存在的Pro108与抗Pro108抗体接触,以及减轻或治疗哺乳动物中Pro108表达的癌症的方法,包括给予治疗 有效量的抗Pro108抗体。

    Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk
    5.
    发明申请
    Pro108 Antibody Compositions and Methods of Use and Use of Pro108 to Assess Cancer Risk 审中-公开
    Pro108抗体组合物和使用和使用Pro108评估癌症风险的方法

    公开(公告)号:US20120329079A1

    公开(公告)日:2012-12-27

    申请号:US13438427

    申请日:2012-04-03

    IPC分类号: G01N33/53 C07K16/18

    摘要: A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided.

    摘要翻译: 提供了一种综合评估Pro108和前列腺特异抗原(PSA)两种前列腺癌风险的方法。 还提供了使用Pro108或Pro108的特异性抗体来评估癌症风险的方法。 还提供了在体内在哺乳动物细胞上结合Pro108的抗体以及可以在制品或试剂盒中提供的包含抗Pro108抗体和载体的组合物。 编码抗Pro108抗体的分离的核酸,包含分离的核酸的表达载体,产生抗Pro108抗体的细胞和产生抗-Pro108抗体的方法以及使用抗体杀死 还提供了表达Pro108的癌细胞并减轻或治疗哺乳动物中Pro108表达的癌症。

    OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
    6.
    发明申请
    OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE 审中-公开
    OVR115抗体组合物及其使用方法

    公开(公告)号:US20130022539A1

    公开(公告)日:2013-01-24

    申请号:US13523393

    申请日:2012-06-14

    摘要: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.

    摘要翻译: 本发明提供在体内在哺乳动物细胞上结合Ovr115的分离的抗卵巢,胰腺,肺或乳腺癌抗原(Ovr115)抗体。 本发明还包括包含抗Ovr115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Ovr115抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Ovr115抗体的细胞。 本发明包括产生抗Ovr115抗体的方法。 本发明的其它方面是杀死表达Ovr115的癌细胞的方法,包括使癌细胞与抗Ovr115抗体接触,以及减轻或治疗哺乳动物中表达Ovr115的癌症的方法,包括给予治疗有效量 的抗Ovr115抗体。

    Ovr115 antibody compositions and methods of use
    7.
    发明授权
    Ovr115 antibody compositions and methods of use 有权
    Ovr115抗体组合物和使用方法

    公开(公告)号:US08207311B2

    公开(公告)日:2012-06-26

    申请号:US10556478

    申请日:2004-05-17

    摘要: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.

    摘要翻译: 本发明提供在体内在哺乳动物细胞上结合Ovr115的分离的抗卵巢,胰腺,肺或乳腺癌抗原(Ovr115)抗体。 本发明还包括包含抗Ovr115抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Ovr115抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Ovr115抗体的细胞。 本发明包括产生抗Ovr115抗体的方法。 本发明的其它方面是杀死表达Ovr115的癌细胞的方法,包括使癌细胞与抗Ovr115抗体接触,以及减轻或治疗哺乳动物中表达Ovr115的癌症的方法,包括给予治疗有效量 的抗Ovr115抗体。

    OVR110 Antibody Compositions and Methods of Use
    8.
    发明申请
    OVR110 Antibody Compositions and Methods of Use 审中-公开
    OVR110抗体组合物和使用方法

    公开(公告)号:US20100209438A1

    公开(公告)日:2010-08-19

    申请号:US12576313

    申请日:2009-10-09

    摘要: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.

    摘要翻译: 本发明提供了在哺乳动物体内与Ovr110结合时内化的分离的抗卵巢,胰腺,肺或乳腺癌抗原(Ovr110)抗体。 本发明还包括包含抗Ovr110抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Ovr110抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Ovr110抗体的细胞。 本发明包括产生抗Ovr110抗体的方法。 本发明的其它方面是杀死表达Ovr110的癌细胞的方法,包括使癌细胞与抗Ovr110抗体接触,以及减轻或治疗哺乳动物中表达Ovr110的癌症的方法,包括给予治疗有效量 的抗Ovr110抗体。

    Pro104 antibody compositions and methods of use
    10.
    发明授权
    Pro104 antibody compositions and methods of use 有权
    Pro104抗体组合物和使用方法

    公开(公告)号:US08080650B2

    公开(公告)日:2011-12-20

    申请号:US12354047

    申请日:2009-01-15

    IPC分类号: C07H21/04

    摘要: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.

    摘要翻译: 本发明提供在体内在哺乳动物细胞上结合Pro104的分离的抗卵巢,胰腺,肺或乳腺癌抗原(Pro104)抗体。 本发明还包括包含抗Pro104抗体和载体的组合物。 这些组合物可以在制品或试剂盒中提供。 本发明的另一方面是编码抗Pro104抗体的分离的核酸,以及包含分离的核酸的表达载体。 还提供产生抗Pro104抗体的细胞。 本发明包括产生抗Pro104抗体的方法。 本发明的其它方面是杀死表达Pro104的癌细胞的方法,包括使癌细胞与抗Pro104抗体接触,以及减轻或治疗哺乳动物中表达Pro104的癌症的方法,包括给予治疗有效量 的抗Pro104抗体。